1 citations · 2 across the 4 of their papers we have counts for
6 papers
Introducing precision-weighted bias as a performance measure to inform the inclusion of adaptive designs in meta-analysis
Martin Law, David S. Robertson, Sofia S. Villar +4
We propose a novel, intuitive measure of statistical performance: precision-weighted bias. Precision-weighted bias is defined as the unconditional bias of an estimator weighted by…
Confidence intervals for adaptive trial designs II: Case study and practical guidance
David S. Robertson, Thomas Burnett, Babak Choodari-Oskooei +4
In adaptive clinical trials, the conventional confidence interval (CI) for a treatment effect is prone to undesirable properties such as undercoverage and potential inconsistency w…
Confidence intervals for adaptive trial designs I: A methodological review
David S. Robertson, Thomas Burnett, Babak Choodari-Oskooei +4
Regulatory guidance notes the need for caution in the interpretation of confidence intervals (CIs) constructed during and after an adaptive clinical trial. Conventional CIs of the…
Point estimation for adaptive trial designs II: practical considerations and guidance
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo +3
In adaptive clinical trials, the conventional end-of-trial point estimate of a treatment effect is prone to bias, that is, a systematic tendency to deviate from its true value. As…
Point estimation for adaptive trial designs I: a methodological review
David S. Robertson, Babak Choodari-Oskooei, Munya Dimairo +3
Recent FDA guidance on adaptive clinical trial designs defines bias as "a systematic tendency for the estimate of treatment effect to deviate from its true value", and states that…
Adding new experimental arms to randomised clinical trials: impact on error rates
Babak Choodari-Oskooei, Daniel J Bratton, Melissa R Gannon +3
Background: Experimental treatments pass through various stages of development. If a treatment passes through early phase experiments, the investigators may want to assess it in a…